Both in vitro and in vivo experiments confirmed that BYJHD inhibits the progression of NSCLC by exerting anti-angiogenic effects, specifically through the inhibition of the ACVRL-1/Smad/ID-1 signaling pathway and the downregulation of CD34. Here, ACVRL1 is linked to non-small cell lung carcinoma.